

Alberto Zamã²

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/576169/publications.pdf>

Version: 2024-02-01

109
papers

4,721
citations

159585

30
h-index

102487

66
g-index

110
all docs

110
docs citations

110
times ranked

7166
citing authors

#	ARTICLE	IF	CITATIONS
1	Aberrant Wnt/ β -Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis. <i>American Journal of Pathology</i> , 2003, 162, 1495-1502.	3.8	625
2	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. <i>Nature Medicine</i> , 2005, 11, 623-629.	30.7	406
3	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 516-532.	16.8	378
4	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. <i>Oncogene</i> , 2002, 21, 1038-1047.	5.9	354
5	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , 2013, 122, 2673-2682.	1.4	208
6	ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 347-357.	4.1	172
7	Gene Expression Profiling Uncovers Molecular Classifiers for the Recognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms. <i>Journal of Clinical Oncology</i> , 2010, 28, 1583-1590.	1.6	152
8	Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 520-528.e5.	2.9	118
9	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. <i>Blood</i> , 2012, 120, 1274-1281.	1.4	101
10	Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. <i>Molecular Cancer</i> , 2010, 9, 273.	19.2	99
11	Group 3 innate lymphoid cells regulate neutrophil migration and function in human decidua. <i>Mucosal Immunology</i> , 2016, 9, 1372-1383.	6.0	99
12	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020, 105, 1604-1612.	3.5	96
13	Role of disease-causing genes in sporadic pancreatic endocrine tumors: <i>MEN1</i> and <i>VHL</i> . <i>Genes Chromosomes and Cancer</i> , 2001, 32, 177-181.	2.8	95
14	Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2006, 7, 95.	3.6	89
15	MicroRNA profiles of t(14;18) negative follicular lymphoma support a late germinal center B-cell phenotype. <i>Blood</i> , 2011, 118, 5550-5558.	1.4	77
16	CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. <i>Histopathology</i> , 2013, 63, 780-787.	2.9	77
17	Diagnostic utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT-PCR study. <i>Modern Pathology</i> , 2007, 20, 722-728.	5.5	72
18	CD10 is expressed in a subset of chromophobe renal cell carcinomas. <i>Modern Pathology</i> , 2004, 17, 1455-1463.	5.5	67

#	ARTICLE	IF	CITATIONS
19	Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. <i>Cellular Oncology</i> (Dordrecht), 2011, 34, 141-153.	4.4	65
20	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 544-562.	1.2	64
21	Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. <i>Osteoporosis International</i> , 2016, 27, 2411-2421.	3.1	61
22	Wiskottâ€Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. <i>Nature Medicine</i> , 2019, 25, 130-140.	30.7	57
23	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	1.4	53
24	Constitutive expression of ?N-p63? isoform in human thymus and thymic epithelial tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 175-183.	2.8	47
25	Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2620-2626.	1.3	43
26	Multivariate statistical tools applied to the characterization of the proteomic profiles of two human lymphoma cell lines by two-dimensional gel electrophoresis. <i>Electrophoresis</i> , 2006, 27, 484-494.	2.4	35
27	The TNF-Family Cytokine TL1A Inhibits Proliferation of Human Activated B Cells. <i>PLoS ONE</i> , 2013, 8, e60136.	2.5	34
28	Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome. <i>Clinical Cancer Research</i> , 2015, 21, 5164-5172.	7.0	33
29	Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis. <i>Antioxidants and Redox Signaling</i> , 2018, 28, 1-14.	5.4	33
30	B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation. <i>Blood</i> , 2021, 138, 1053-1066.	1.4	33
31	HHV-8 and EBV are not commonly found in idiopathic pulmonary fibrosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2005, 22, 123-8.	0.2	33
32	ZAPâ€70 expression is associated with increased risk of autoimmune cytopenias in CLL patients. <i>American Journal of Hematology</i> , 2010, 85, 494-498.	4.1	31
33	slan+ Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP. <i>Cancer Research</i> , 2018, 78, 3544-3559.	0.9	31
34	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. <i>Cancer Research</i> , 2018, 78, 3413-3420.	0.9	31
35	Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing. <i>Leukemia</i> , 2018, 32, 685-693.	7.2	29
36	Signal transduction pathways of mantle cell lymphoma: A phosphoproteomeâ€based study. <i>Proteomics</i> , 2008, 8, 4495-4506.	2.2	28

#	ARTICLE	IF	CITATIONS
37	GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2009, 144, 317-331.	2.5	28
38	Analysis of colorectal cancers for human cytomegalovirus presence. <i>Infectious Agents and Cancer</i> , 2009, 4, 6.	2.6	27
39	Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. <i>American Journal of Hematology</i> , 2012, 87, 22-25.	4.1	27
40	The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis. <i>Leukemia Research</i> , 2015, 39, 273-278.	0.8	27
41	Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas. <i>Modern Pathology</i> , 2005, 18, 1448-1453.	5.5	25
42	Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma. <i>Haematologica</i> , 2006, 91, 40-7.	3.5	25
43	The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion. <i>British Journal of Haematology</i> , 2018, 180, 391-394.	2.5	24
44	Molecular characterization of composite mantle cell and follicular lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 639-643.	2.8	23
45	Proteomic analysis of lymphoid and haematopoietic neoplasms: There's more than biomarker discovery. <i>Journal of Proteomics</i> , 2010, 73, 508-520.	2.4	22
46	Improvement of maternal and fetal outcomes in women with sickle cell disease treated with early prophylactic erythrocytapheresis. <i>Transfusion</i> , 2018, 58, 2192-2201.	1.6	22
47	Induction of Apoptosis in Jeko-1 Mantle Cell Lymphoma Cell Line by Resveratrol: A Proteomic Analysis. <i>Journal of Proteome Research</i> , 2008, 7, 2670-2680.	3.7	21
48	Application of Microfluidic Technology to the BIOMED-2 Protocol for Detection of B-Cell Clonality. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 30-37.	2.8	21
49	Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 781-793.	2.5	21
50	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , 2018, 103, 849-856.	3.5	21
51	Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome. <i>European Journal of Haematology</i> , 2020, 105, 468-475.	2.2	21
52	Pesticide toxicogenomics across scales: in vitro transcriptome predicts mechanisms and outcomes of exposure in vivo. <i>Scientific Reports</i> , 2016, 6, 38131.	3.3	20
53	Primary role of multiparametric flow cytometry in the diagnostic workup of indolent clonal mast cell disorders. <i>Cytometry Part B - Clinical Cytometry</i> , 2011, 80B, 362-368.	1.5	18
54	Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment. <i>Leukemia and Lymphoma</i> , 2019, 60, 3395-3405.	1.3	18

#	ARTICLE	IF	CITATIONS
55	Microfluidic Deletion/Insertion Analysis for Rapid Screening of KIT and PDGFRA Mutations in CD117-Positive Gastrointestinal Stromal Tumors. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 151-157.	2.8	13
56	A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 513-518.	2.8	13
57	MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. <i>Oncotarget</i> , 2018, 9, 29753-29771.	1.8	13
58	Reactive Eosinophil Proliferations in Tissue and the Lymphocytic Variant of Hypereosinophilic Syndrome. <i>American Journal of Clinical Pathology</i> , 2021, 155, 211-238.	0.7	12
59	VDJSeq-Solver: In Silico V(D)J Recombination Detection Tool. <i>PLoS ONE</i> , 2015, 10, e0118192.	2.5	12
60	MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. <i>Oncotarget</i> , 2018, 9, 19961-19979.	1.8	11
61	Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 32061-32074.	1.8	11
62	Proteomics of human cancer tissues and cells. <i>TrAC - Trends in Analytical Chemistry</i> , 2011, 30, 346-359.	11.4	9
63	Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 677-685.	2.8	9
64	In reply to Schäfer <i>et al</i> : new evidence on the role of endothelin-1 axis as a potential therapeutic target in multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 1052-1055.	2.5	9
65	9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAH trial. <i>British Journal of Haematology</i> , 2022, 196, 116-126.	2.5	9
66	Chromium-induced diffuse dermatitis with lymph node involvement resulting from Langerhans cell histiocytosis after metal-on-metal hip resurfacing. <i>British Journal of Dermatology</i> , 2015, 172, 1633-1636.	1.5	8
67	Improved Detection of the KIT D816V Mutation Using a Real-Time PCR Assay Allows a Finer Recognition of Patients with Indolent Systemic Mastocytosis. <i>Blood</i> , 2011, 118, 5163-5163.	1.4	8
68	VR09 Cell Line: An EBV-Positive Lymphoblastoid Cell Line with In Vivo Characteristics of Diffuse Large B Cell Lymphoma of Activated B-Cell Type. <i>PLoS ONE</i> , 2012, 7, e52811.	2.5	7
69	Mantle cell lymphoma cell lines show no evident immunoglobulin heavy chain stereotypy but frequent light chain stereotypy. <i>Leukemia and Lymphoma</i> , 2013, 54, 1747-1755.	1.3	7
70	Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-15.	2.1	7
71	Diagnosis of classic Hodgkin lymphoma on bone marrow biopsy. <i>Histopathology</i> , 2020, 76, 934-941.	2.9	7
72	Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2018, 132, 401-401.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage. <i>Blood Advances</i> , 2021, 5, 4890-4900.	5.2	7
74	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. <i>Blood Advances</i> , 2021, 5, 5239-5257.	5.2	7
75	Benign acute viral myositis in African migrants: A clinical, serological, and pathological study. <i>Muscle and Nerve</i> , 2019, 60, 586-590.	2.2	6
76	Lymphomatosis cerebri and anti-NMDAR antibodies: A unique constellation. <i>Journal of the Neurological Sciences</i> , 2019, 398, 19-21.	0.6	6
77	NOTCH1 Mutated IGHV Unmutated Chronic Lymphocytic Leukemia Cells Are Characterized By a Constitutive Overexpression of Nucleophosmin-1 and Ribosome-Associated Components. <i>Blood</i> , 2014, 124, 3308-3308.	1.4	6
78	<sc>Epstein-Barr Virus</sc> infection patterns in nodular lymphocyte predominant Hodgkin lymphoma. <i>Histopathology</i> , 2022, , .	2.9	6
79	Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 1988-1991.	0.5	5
80	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. <i>Haematologica</i> , 2019, 104, e410-e414.	3.5	5
81	Rapid reconstitution of functionally active 6-sulfoLacNAc+dendritic cells (slanDCs) of donor origin following allogeneic haematopoietic stem cell transplant. <i>Clinical and Experimental Immunology</i> , 2014, 178, 129-141.	2.6	4
82	Tissue proteomics of splenic marginal zone lymphoma. <i>Electrophoresis</i> , 2015, 36, 1612-1621.	2.4	4
83	CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients. <i>Annals of Hematology</i> , 2019, 98, 2339-2346.	1.8	4
84	Aggressive B-cell lymphomas with a primary bone marrow presentation. <i>Histopathology</i> , 2020, 77, 369-379.	2.9	4
85	The histological and molecular spectrum of lipoblastoma: A case series with identification of three novel gene fusions by targeted RNA-sequencing. <i>Pathology Research and Practice</i> , 2021, 226, 153591.	2.3	4
86	An unusual case of sarcoidosis in an adult patient with sickle cell disease: Management with methotrexate and low dose of steroid. <i>American Journal of Hematology</i> , 2013, 88, 243-243.	4.1	3
87	Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. <i>Hematological Oncology</i> , 2019, 37, 628-633.	1.7	3
88	Droplet Digital PCR Assay for <i>MYD88</i>^{<i>L265P</i>}: Clinical Applications in Waldenström Macroglobulinemia. <i>HemaSphere</i> , 2020, 4, e324.	2.7	3
89	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. , 0,		3
90	Elastin Microfibril Interfacer1 (EMILIN1) is an alternative prosurvival VLA4 ligand in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 181-190.	1.7	3

#	ARTICLE	IF	CITATIONS
91	Lack of expression of TUBB3 characterizes both BCL2-positive and BCL2-negative follicular lymphoma. <i>Modern Pathology</i> , 2014, 27, 808-813.	5.5	2
92	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 744.	16.8	2
93	Recurrence of severe low back pain due to myeloproliferative disorder in a patient affected by seronegative spondyloarthritis. <i>Rheumatology International</i> , 2012, 32, 1845-1846.	3.0	1
94	Hairy cell leukemia in kidney transplantation: lesson from a rare disorder. <i>Experimental Hematology and Oncology</i> , 2013, 2, 22.	5.0	1
95	A rare disorder in an orphan disease: Kikuchi's Fujimoto disease in a young adult patient with sickle cell anemia. <i>American Journal of Hematology</i> , 2014, 89, 1151-1152.	4.1	1
96	Unusual case of iron overload with cancer-mimicking abdominal splenosis. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223410.	0.5	1
97	Challenges and limitations in the primary diagnosis of T-cell and natural killer cell/T-cell lymphoma in bone marrow biopsy. <i>Histopathology</i> , 2020, 77, 2-17.	2.9	1
98	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , 2011, 118, 263-263.	1.4	1
99	Abstract PR10: FBXO11 is recurrently mutated in Burkitt lymphoma and its inactivation accelerates lymphomagenesis in $\frac{1}{4}$ -myc mice. , 2017, , .		1
100	Combined Genetic Lesions in TP53 and CDKN2A/CDKN2B Drive B Cell Receptor-Dependent/Costimulatory Signal-Independent Proliferation in Richter Syndrome. <i>Blood</i> , 2020, 136, 5-6.	1.4	1
101	Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure. <i>Hematology Reports</i> , 2017, 9, 7091.	0.8	0
102	In Vitro and In Vivo Model of EBV-Positive Non-Hodgkin Plasmablastic Lymphoma with Focal Plasmacytic Differentiation. <i>Blood</i> , 2011, 118, 2668-2668.	1.4	0
103	Nucleophosmin-1 and Ribosome-Associated Components Are Constitutively Overexpressed in NOTCH1 Mutated IGHV Unmutated CLL. <i>Blood</i> , 2012, 120, 3880-3880.	1.4	0
104	Detection of allele-specific gene expression on Next Generation Sequencing data. <i>EMBnet Journal</i> , 2012, 18, 130.	0.6	0
105	The Elastin Microfibril Interfacer-1 (EMILIN-1) Is a Ligand for CD49d in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2012, 120, 1772-1772.	1.4	0
106	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. <i>Blood</i> , 2013, 122, 77-77.	1.4	0
107	The TNF-Family Cytokine TL1A/Death Receptor 3 System Reduces Metabolic Activity in Chronic Lymphocytic Leukemia B Cells. <i>Blood</i> , 2014, 124, 3313-3313.	1.4	0
108	FBXO11, a Regulator of BCL6 Stability, Is Recurrently Mutated in Burkitt Lymphoma. <i>Blood</i> , 2015, 126, 3673-3673.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway. Blood, 2015, 126, 701-701.	1.4	0